Research has demonstrated that the downregulation of ADH5 is a feature of primary hepatocellular carcinoma, and its pharmacological inhibition by inducible nitric oxide synthase (iNOS) presents a promising treatment option for individuals with primary hepatocellular carcinoma [8, 9]. The gene discussed is ADH5; the disease is hepatocellular carcinoma.